PERSANTIN |
PERSANTIN RET |
CEREBROVASE 100 |
PYRIDANTIN |
B01AC07 |
RA-8 |
IV PERSANTINE |
CEREBROVASE 25 |
MODAPLATE |
PERSANTINE |
DIPYRIDAMOLE |
ATTIA |
VASYROL |
NSC-515776 |
OFCRAM PR |
PERSANTINE® |
DIPYRIDAMINE |
DIPYUDAMINE |
DIPYRIDAMOLUM |
DIPIRIDAMOL |
DYPYRIDAMOL |
CURANTYL |
CLERIDIUM 150 |
pubchem.compound:3108 |
rxcui:3521 |
chembl:CHEMBL932 |
chemidplus:58-32-2 |
drugbank:00975 |
Drug Class | vasodilator agents |
Year of Approval | 1961 |
Drug Class | platelet aggregation inhibitors |
Drug Indications | antithrombotic |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | anticoagulant |
Drug Categories | anticoagulants |
Drug Categories | antiplatelet agents |
Drug Categories | bsep/abcb11 substrates |
Drug Categories | decreased platelet aggregation |
Drug Categories | miscellaneous vasodilatating agents |
Drug Categories | oatp1b1/slco1b1 inhibitors |
Drug Categories | oatp1b3 inhibitors |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | phosphodiesterase 5 inhibitors |
Drug Categories | vasodilating agents |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Trial Name | CRx-102, prednisolone plus dipyridamole,Synavive |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | CRx-102, prednisolone plus dipyridamole,Synavive |
Novel drug target | Established target |
Trial Name | CRx-150, amoxapine plus dipyridamole |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | CRx-150, amoxapine plus dipyridamole |
Novel drug target | Established target |
Trial Name | CRx-102, prednisolone plus dipyridamole,Synavive |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
Trial Name | CRx-102, prednisolone plus dipyridamole,Synavive |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
DIPYRIDAMOLE | DrugBank Drug Name |
58-32-2 | CAS Number |
Aggrenox | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | anticoagulants |
DIPYRIDAMOLE | Primary Drug Name |
Drug Class | platelet aggregation inhibitors |
Year of Approval | 1961 |
Drug Class | vasodilator agents |
Drug Indications | anticoagulant |
Drug Class | Small Molecule |
FDA Approval | approved |
C445 | NCI drug code |
DIPYRIDAMOLE | GuideToPharmacology Ligand Name |
D0F9GE | TTD Drug ID |
CHEMBL932 | ChEMBL Drug ID |